EU Antitrust Regulators to Deliver Verdict on Novo Holdings’ Catalent Acquisition by December 6
The European Commission is set to announce its decision on the proposed acquisition of contract drug manufacturer Catalent by Novo Holdings, the primary shareholder of pharmaceutical giant Novo Nordisk, by December 6, 2024. This follows an official submission for approval filed by Novo Holdings on October 31, as noted on the Commission’s website. The decision […]
Continue Reading